BPN14770 ( DrugBank: BPN-14770 )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
206	脆弱Ｘ症候群	2

206. 脆弱Ｘ症候群

---

臨床試験数 : 104 /  薬物数 : 87 - (DrugBank : 32) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 79

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05163808 (ClinicalTrials.gov)	December 15, 2021	15/12/2021	A Randomized Study of BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X Syndrome	A Randomized, Double-blind, Placebo-controlled, Two-Part Study of High and Low Dose BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X Syndrome	Fragile X Syndrome	Drug: zatolmilast;Drug: Placebo	Tetra Discovery Partners	NULL	Not yet recruiting	12 Years	18 Years	Male	150	Phase 2/Phase 3	NULL
2	NCT03569631 (ClinicalTrials.gov)	July 9, 2018	25/5/2018	A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome	A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome	Fragile X Syndrome;FXS;Fra(X) Syndrome	Drug: BPN14770;Drug: Placebo	Tetra Discovery Partners	NULL	Completed	18 Years	45 Years	Male	30	Phase 2	United States